From the Department of Neurology (J.H.S., J.-Y.L., H.N.), Seoul Metropolitan Government-Seoul National University Boramae Medical Center and Seoul National University College of Medicine; Department of Nuclear Medicine (Y.-K.K., S.-A.S., H.K.), Seoul Metropolitan Government-Seoul National University Boramae Medical Center; and Department of Neurology (B.J.), Seoul National University Hospital and Seoul National University College of Medicine, South Korea.
Neurology. 2020 Dec 8;95(23):e3081-e3092. doi: 10.1212/WNL.0000000000010942. Epub 2020 Sep 28.
To elucidate longitudinal changes in the dopamine transporter (DAT) availability in association with the prodromal markers in idiopathic REM sleep behavior disorder (iRBD), we analyzed a longitudinal prospective iRBD cohort data.
The study cohort consisted of patients with iRBD, individuals with Parkinson disease (PD), and healthy controls. All participants were evaluated for olfaction, neuropsychological tests, and the Movement Disorders Society-Unified Parkinson's Disease Rating Scale and underwent F-FP-CIT PET scans every 2 years. We calculated the DAT pattern by performing the principal component analysis of tracer uptakes in 6 striatal regions.
DAT patterns in patients with iRBD with baseline hyposmia, constipation, and mild parkinsonian signs distributed toward the PD pattern and clearly distinguished from the healthy control pattern. The DAT pattern moved toward the PD pattern over time in some patients with iRBD during the follow-up, and baseline hyposmia was the only biomarker significantly associated with this change. Baseline PD pattern of DAT predicted 58% of disease converters (hazard ratio 4.95 [95% confidence interval 1.16-21.08]). The combination of hyposmia and baseline PD pattern of DAT predicted 67% of the conversion (hazard ratio 7.89 [confidence interval 1.85-33.69]). The estimated sample size required for a simulated neuroprotective clinical trial was 63 per group when the annual change of DAT pattern was used as an outcome in the subgroup with baseline DAT PD pattern and hyposmia, which is the smallest number reported so far.
Baseline and longitudinal monitoring of the DAT pattern can be a useful biomarker in identifying individuals with a high risk of disease conversion and in selecting the potential population for clinical trials in iRBD.
通过分析特发性 REM 睡眠行为障碍(iRBD)的纵向前瞻性 iRBD 队列数据,阐明与前驱标志物相关的多巴胺转运体(DAT)可用性的纵向变化。
研究队列包括 iRBD 患者、帕金森病(PD)患者和健康对照者。所有参与者均接受嗅觉评估、神经心理学测试和运动障碍协会统一帕金森病评定量表(MDS-UPDRS)评估,并每 2 年进行一次 F-FP-CIT PET 扫描。我们通过对 6 个纹状体区域的示踪剂摄取进行主成分分析来计算 DAT 模式。
基线嗅觉减退、便秘和轻度帕金森病体征的 iRBD 患者的 DAT 模式向 PD 模式分布,并与健康对照组模式明显区分。在随访过程中,一些 iRBD 患者的 DAT 模式随时间向 PD 模式移动,而基线嗅觉减退是唯一与这种变化显著相关的生物标志物。DAT 基线 PD 模式预测了 58%的疾病转化者(风险比 4.95 [95%置信区间 1.16-21.08])。DAT 基线嗅觉减退和 PD 模式的组合预测了 67%的转化(风险比 7.89 [置信区间 1.85-33.69])。当使用 DAT 模式的年度变化作为基线 DAT PD 模式和嗅觉减退亚组的结果时,模拟神经保护临床试验所需的估计样本量为每组 63 例,这是迄今为止报告的最小数字。
DAT 模式的基线和纵向监测可以作为识别疾病转化风险较高个体的有用生物标志物,并有助于选择 iRBD 临床试验的潜在人群。